Open AccessP1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE
Author(s) -
Belada D.,
Leppä S.,
Wahlin B. E.,
Nijland M.,
Christensen J. H.,
Vos S.,
Holte H.,
Linton K. M.,
Abbas A.,
Wang L.,
Dinh M.,
Elliott B.,
Falchi L.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847408.61609.bd
Subject(s) - lenalidomide , medicine , follicular lymphoma , regimen , refractory (planetary science) , rituximab , follicular phase , gastroenterology , neutropenia , lymphoma , dosing , oncology , urology , surgery , toxicity , multiple myeloma , biology , astrobiology